Cellectis Completes Sale of $47 million through its ATM program
April 09 2021 - 2:30AM
Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the
“Company”), a clinical-stage biotechnological company employing its
core proprietary technologies to develop best-in-class products
based on gene-edited allogeneic CAR T-cells in the field of
immuno-oncology, today announced that it has completed sales of
approximately $47 million of American Depositary Shares (“ADS”)
pursuant to the Company’s ATM program established on March 29, 2021
(the “ATM Sales”), through Jefferies LLC (“Jefferies”), acting as
sales agent. Each ADS represents one ordinary share of the Company.
In the ATM Sales, an aggregate of 2,415,630 new
ADSs and the same number of underlying new ordinary shares have
been issued to existing and new investors at an at-the-market price
of $19.50 per new ADS.
It is anticipated that the settlement and
delivery of the new ordinary shares will take place on April 12,
2021. They will be admitted to trading on the market of Euronext
Growth and the issued ADSs will trade on Nasdaq.
A shelf registration statement on Form F-3
(including a prospectus) relating to Cellectis’ securities was
filed with the SEC and became effective upon filing on June 2,
2020. Before purchasing ADSs in the offering, prospective investors
should read the prospectus supplement and the accompanying
prospectus, together with the documents incorporated by reference
therein. Prospective investors may obtain these documents for free
by visiting EDGAR on the SEC’s website at www.sec.gov.
Alternatively, a copy of the prospectus supplement (and
accompanying prospectus) relating to the offering may be obtained
from Jefferies LLC, 520 Madison Avenue, New York, NY 10022 or by
telephone at (877) 821-7388 or by email at
Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy securities of the
Company, nor shall there be any sale of such securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful. In particular, no public offering of ADSs has
been made in Europe.
Special Note Regarding Forward-Looking
Statements
This press release contains “forward-looking”
statements within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995, including,
but not limited to, statements regarding Cellectis’ securities
offering and the settlement thereof. Words such as “anticipates,”
“believes,” “expects,” “intends,” “projects,” “anticipates,” and
“future” or similar expressions are intended to identify
forward-looking statements. These forward-looking statements
involve known and unknown risks, uncertainties and other factors
that may cause Cellectis’ actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Further information on the risk factors
that may affect company business and financial performance is
included in Cellectis’ Annual Report on Form 20-F for the year
ended December 31, 2020, and subsequent filings Cellectis makes
with the SEC from time to time. Except as required by law,
Cellectis assumes no obligation to update these forward-looking
statements publicly, or to update the reasons actual results could
differ materially from those anticipated in the forward-looking
statements, even if new information becomes available in the
future, except as required by law.
For further information, please contact:
Media contacts:
Margaret Gandolfo, 646-628-0300,Communications
ManagerMargaret.gandolfo@cellectis.com
or
Conor McGlodrick, 914-355-0927,Zeno
GroupConor.Mcgoldrick@zenogroup.com
IR contact:
Simon Harnest, 646-385-9008Chief Investment
Officersimon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Oct 2023 to Oct 2024